Edesa Biotech Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Selling, General & Admin	5.55	4.24	4.13	4.43	5.04	5.73
Research & Development	9.08	3.67	2.88	4.79	13.34	17.95
Operating Expenses	14.63	7.91	7.01	9.22	18.37	23.68
Operating Income	-14.63	-7.91	-7.01	-9.22	-18.37	-23.68
Interest & Investment Income	0	0	0.15	0.29	0.06	0.01
Currency Exchange Gain (Loss)	0	-0.06	-0.02	-0.02	-0.02	-0.01
EBT Excluding Unusual Items	-14.89	-7.97	-6.88	-8.95	-18.33	-23.68
Other Unusual Items	0.78	0.78	0.71	0.58	0.78	10.34
Pretax Income	-14.1	-7.18	-6.17	-8.37	-17.55	-13.34
Income Tax Expense	0	0	0	0	0	0
Net Income	-14.1	-7.19	-6.17	-8.37	-17.55	-13.34
Net Income to Common	-14.1	-7.19	-6.17	-8.37	-17.55	-13.34
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	8	6	3	3	2	2
Shares Outstanding (Diluted)	8	6	3	3	2	2
Shares Change	72.33%	77.54%	11.84%	36.37%	21.50%	40.32%
EPS (Basic)	-1.73	-1.27	-1.93	-2.93	-8.37	-7.73
EPS (Diluted)	-1.73	-1.27	-1.93	-2.93	-8.37	-7.73
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Free Cash Flow	-8.91	-7.32	-4.89	-6.64	-12.28	-13.67
Free Cash Flow Per Share	-1.09	-1.29	-1.53	-2.32	-5.86	-7.92
EBITDA	-14.53	-7.79	-6.83	-9.12	-18.26	-23.57
D&A For EBITDA	0.1	0.12	0.19	0.11	0.11	0.11
EBIT	-14.63	-7.91	-7.01	-9.22	-18.37	-23.68

SEC Filings: 10-K · 10-Q